Cargando…
A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335117/ https://www.ncbi.nlm.nih.gov/pubmed/35443566 http://dx.doi.org/10.3324/haematol.2022.280629 |
| _version_ | 1784759264633421824 |
|---|---|
| author | Yang, Min Zhang, Wenhao Yu, Kang Wang, Peng Jiang, Hua Chen, Linjun Meng, Haitao Weng, Yiqin Tao, Rong Huang, Xin Xing, Chongyun Wang, Huamao Wan, Jiangbo Wang, Shasha Dai, Lihui Hendrix, Amanda Y. Xiao, Jun Wang, Wei Ma, Hong Hao, Siguo Jin, Jie Li, Zonghai Jiang, Songfu |
| author_facet | Yang, Min Zhang, Wenhao Yu, Kang Wang, Peng Jiang, Hua Chen, Linjun Meng, Haitao Weng, Yiqin Tao, Rong Huang, Xin Xing, Chongyun Wang, Huamao Wan, Jiangbo Wang, Shasha Dai, Lihui Hendrix, Amanda Y. Xiao, Jun Wang, Wei Ma, Hong Hao, Siguo Jin, Jie Li, Zonghai Jiang, Songfu |
| author_sort | Yang, Min |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9335117 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93351172022-08-26 A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials Yang, Min Zhang, Wenhao Yu, Kang Wang, Peng Jiang, Hua Chen, Linjun Meng, Haitao Weng, Yiqin Tao, Rong Huang, Xin Xing, Chongyun Wang, Huamao Wan, Jiangbo Wang, Shasha Dai, Lihui Hendrix, Amanda Y. Xiao, Jun Wang, Wei Ma, Hong Hao, Siguo Jin, Jie Li, Zonghai Jiang, Songfu Haematologica Letter to the Editor Fondazione Ferrata Storti 2022-04-21 /pmc/articles/PMC9335117/ /pubmed/35443566 http://dx.doi.org/10.3324/haematol.2022.280629 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letter to the Editor Yang, Min Zhang, Wenhao Yu, Kang Wang, Peng Jiang, Hua Chen, Linjun Meng, Haitao Weng, Yiqin Tao, Rong Huang, Xin Xing, Chongyun Wang, Huamao Wan, Jiangbo Wang, Shasha Dai, Lihui Hendrix, Amanda Y. Xiao, Jun Wang, Wei Ma, Hong Hao, Siguo Jin, Jie Li, Zonghai Jiang, Songfu A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials |
| title | A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials |
| title_full | A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials |
| title_fullStr | A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials |
| title_full_unstemmed | A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials |
| title_short | A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials |
| title_sort | novel bcma car-t-cell therapy with optimized human scfv for treatment of relapsed/refractory multiple myeloma: results from phase i clinical trials |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335117/ https://www.ncbi.nlm.nih.gov/pubmed/35443566 http://dx.doi.org/10.3324/haematol.2022.280629 |
| work_keys_str_mv | AT yangmin anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT zhangwenhao anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT yukang anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT wangpeng anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT jianghua anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT chenlinjun anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT menghaitao anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT wengyiqin anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT taorong anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT huangxin anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT xingchongyun anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT wanghuamao anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT wanjiangbo anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT wangshasha anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT dailihui anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT hendrixamanday anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT xiaojun anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT wangwei anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT mahong anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT haosiguo anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT jinjie anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT lizonghai anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT jiangsongfu anovelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT yangmin novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT zhangwenhao novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT yukang novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT wangpeng novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT jianghua novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT chenlinjun novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT menghaitao novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT wengyiqin novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT taorong novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT huangxin novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT xingchongyun novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT wanghuamao novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT wanjiangbo novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT wangshasha novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT dailihui novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT hendrixamanday novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT xiaojun novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT wangwei novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT mahong novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT haosiguo novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT jinjie novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT lizonghai novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials AT jiangsongfu novelbcmacartcelltherapywithoptimizedhumanscfvfortreatmentofrelapsedrefractorymultiplemyelomaresultsfromphaseiclinicaltrials |